OBJECTIVES These studies conducted analyses to examine patient characteristics and outcomes associated with worsening heart failure (WHF).
, and RELAX-AHF (Relaxin in Acute Heart Failure) (13, 14) . In addition, WHF is a component of the primary endpoint in the ongoing TRUE-
AHF (Trial to Evaluate the Efficacy and Safety of Ularitide [Urodilatin] Intravenous Infusion in Patients
Suffering From Acute Decompensated Heart Failure) trial (NCT01661634).
We designed a pooled analysis of individual patient data from several recent studies of AHF to examine patient characteristics and outcomes associated with WHF.
METHODS STUDIES AND DATA INCLUDED.
A pooled analysis was conducted using patient-level data from the PROTECT (12, 15) and RELAX-AHF phase II/III (14, 16) studies ( Table 1) . In these studies, physicianassessed HF signs and symptoms were collected daily using standard scales and WHF was defined as worsening signs and/or symptoms of HF requiring intensification of IV therapy or mechanical support.
Ethics committee approval was obtained at each site and informed consent obtained from each patient who participated in these studies.
Potential predictors were chosen based on important baseline measures identified and considered in models for similar outcomes developed for the PROTECT (17, 18) and RELAX-AHF (7) studies. Analyses were restricted to data available across all the studies and excluded variables with a high proportion of missing values. Most covariates considered were available for >99% of patients; laboratory parameters had the highest proportion of missing values, with 11% the highest proportion missing (Online Table 1 
RESULTS
PATIENT CHARACTERISTICS. Data from 3,734 patients were included ( Table 1 ). Slight differences in patient characteristics (Online Table 1 Table 1 .
Worsening Heart Failure in the PROTECT and RELAX-AHF Studies Table 2 ). The strongest multivariable predictors of WHF were higher BUN, respiratory rate, hematocrit, and systolic blood pressure, which had a V-shaped association with WHF ( Table 3 ). Online Table 3 *Stratified by study (PROTECT pilot, PROTECT, Pre-RELAX-AHF, and RELAX-AHF). Patients who died or had a censored time by 5 days were excluded from analysis.
IV ¼ intravenous; KM ¼ Kaplan-Meier; other abbreviations as in Tables 1 and 3. for CV death or HF/RF rehospitalization through day 60 from 1.64 to 1.57 (4%), and reduced the HR for death through day 180 from 1.93 to 1.58 (18%). The associations of WHF with these outcomes remained highly significant with all p < 0.0001. 26%, p value not provided) (10), but with a trend toward increased early mortality. In the RELAX-AHF study, serelaxin administration was associated with Mean values and standard errors by day for (A) creatinine, (B) alanine aminotransferase (ALT), and (C) aspartate aminotransferase (AST). WHF ¼ worsening heart failure.
Davison et al. Worsening Heart Failure in the PROTECT and RELAX-AHF Studies 30% or greater reductions in WHF to day 14 and 180-day CV and all-cause mortality, but not with 60-day HF/RF rehospitalization or CV death (14) .
Thus, administration of some IV therapies during the first days of admission for AHF has led to a reduction in the rate of WHF, but this has not translated consistently into improved longer-term outcomes. KEY WORDS acute heart failure, heart failure readmission, mortality, prognosis, renal function, worsening heart failure APPENDIX For supplemental tables, please see the online version of this article. 
